Aligos Therapeutics to Present Six Abstracts at EASL 2024

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in innovative treatments for liver and viral diseases, has announced that six of its abstracts have been accepted for poster presentations at the upcoming European Association for the Study of the Liver (EASL) Congress 2024. The event is scheduled to take place from June 5-8 in Milan, Italy. Among these presentations, two have been identified as top abstracts, marking significant recognition within their respective categories. Details of the abstracts can be accessed on the EASL website.

One of the highlighted abstracts (Abstract #: 603) focuses on ALG-000184, a promising small molecule Capsid Assembly Modulator (CAM-E) for chronic hepatitis B (CHB). The study, headed by Professor Man-Fung Yuen from the University of Hong Kong, reveals that extended treatment with ALG-000184, either alone or combined with Entecavir, is linked to reductions in viral markers and favorable anti-HBeAb trends in HBeAg+ CHB subjects.

Another significant abstract (Abstract #: 895) presented by Kosh Agarwal from King’s College Hospital, delves into the effects of ALG-000184 on untreated HBeAg negative CHB subjects. The findings indicate that ALG-000184 induces potent antiviral effects, including the suppression of HBV DNA/RNA and declines in HBcrAg levels.

Additional research (Abstract #: 2390) by Kha Le explores the association between baseline characteristics and plasma ALG-001075 to HBsAg responses in HBeAg+ CHB subjects following treatment with ALG-000184, with or without Entecavir.

In the preclinical category, Jieun Song (Abstract #: 1298) presents the pharmacological characterization of human PNPLA3-targeting short interfering RNA (siRNA) molecules for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). 

One of the top abstracts (Abstract #: 1338), presented by Jin Hong, showcases second-generation HBV siRNAs with novel chemistries that demonstrate improved profiles compared to ALG-125755 and other clinical stage siRNAs. 

Another top abstract (Abstract #: 1763), by Yannick Debing, highlights the rapid HBsAg reductions induced by non-HAP CAM-A compounds ALG-006746 and ALG-006780 in AAV-HBV mice, along with their favorable pharmacokinetic profiles.

These top abstracts will be prominently displayed throughout the four days of the congress, reflecting their high significance in their respective fields.

Aligos Therapeutics, founded in 2018, aims to be a global leader in the treatment of liver and viral diseases. The company leverages its extensive expertise and decades of drug development experience to discover and develop potentially best-in-class therapeutics for conditions such as MASH and high-need viruses including hepatitis B and coronaviruses.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!